Literature DB >> 18688092

Tau aggregation and toxicity in tauopathic neurodegenerative diseases.

Nicolette S Honson1, Jeff Kuret.   

Abstract

Since its discovery as a structural component of neurofibrillary lesions of Alzheimer's disease more than twenty years ago, tau protein has been implicated in the cascade of events associated with neurodegeneration. Specifically, the "tau hypothesis" posits that misfunction of tau, which occurs in response to unknown stimuli, results in its intracellular assembly into filaments that eventually prove toxic to the cells that produce them. The tau hypothesis is supported by numerous neuropathological and genetic observations of authentic human disease cases. However, experiments designed to study aggregate toxicity in biological models suggest that some aggregate species may be inert or could potentially serve a neuroprotective function. Distinguishing these possibilities experimentally has been complicated by currently available biological models, which do not fully recapitulate aggregation conditions seen in disease. Additional model systems which better approximate physiological conditions may help elucidate the molecular mechanisms involved in aggregation associated toxicity. Here we examine the accumulated evidence linking aggregation and neurodegeneration, and experimental approaches to the problem of tau aggregation-mediated toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688092      PMCID: PMC2748882          DOI: 10.3233/jad-2008-14409

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  62 in total

1.  Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation.

Authors:  Adam D Cash; Gjumrakch Aliev; Sandra L Siedlak; Akihiko Nunomura; Hisashi Fujioka; Xiongwei Zhu; Arun K Raina; Harry V Vinters; Massimo Tabaton; Anne B Johnson; Manuel Paula-Barbosa; Jesus Avíla; Paul K Jones; Rudy J Castellani; Mark A Smith; George Perry
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 2.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

Review 3.  Characterization of paired helical filaments by scanning transmission electron microscopy.

Authors:  Hanna Ksiezak-Reding; Joseph S Wall
Journal:  Microsc Res Tech       Date:  2005-07       Impact factor: 2.769

Review 4.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.

Authors:  Massimo Stefani; Christopher M Dobson
Journal:  J Mol Med (Berl)       Date:  2003-08-27       Impact factor: 4.599

5.  Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.

Authors:  C W Wittmann; M F Wszolek; J M Shulman; P M Salvaterra; J Lewis; M Hutton; M B Feany
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

6.  Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease.

Authors:  Nupur Ghoshal; Francisco García-Sierra; Joanne Wuu; Sue Leurgans; David A Bennett; Robert W Berry; Lester I Binder
Journal:  Exp Neurol       Date:  2002-10       Impact factor: 5.330

7.  Pathological determinants of the transition to clinical dementia in Alzheimer's disease.

Authors:  Donald R Royall; Raymond Palmer; Amy R Mulroy; Marsha J Polk; Gustavo C Román; Jean-Phillippe David; André Delacourte
Journal:  Exp Aging Res       Date:  2002 Apr-Jun       Impact factor: 1.645

8.  Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

Authors:  Jean C Augustinack; Anja Schneider; Eva-Maria Mandelkow; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2002-01       Impact factor: 17.088

9.  Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure.

Authors:  John Berriman; Louise C Serpell; Keith A Oberg; Anthony L Fink; Michel Goedert; R Anthony Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

10.  Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology.

Authors:  Bärbel Schönheit; Rosemarie Zarski; Thomas G Ohm
Journal:  Neurobiol Aging       Date:  2004-07       Impact factor: 4.673

View more
  21 in total

1.  TREM2 Ameliorates Neuronal Tau Pathology Through Suppression of Microglial Inflammatory Response.

Authors:  Teng Jiang; Ying-Dong Zhang; Qing Gao; Zhou Ou; Peng-Yu Gong; Jian-Quan Shi; Liang Wu; Jun-Shan Zhou
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

Review 2.  Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

Authors:  Thimmappa S Anekonda; Joseph F Quinn
Journal:  Biochim Biophys Acta       Date:  2011-09-08

3.  Structural determinants of Tau aggregation inhibitor potency.

Authors:  Kelsey N Schafer; Katryna Cisek; Carol J Huseby; Edward Chang; Jeff Kuret
Journal:  J Biol Chem       Date:  2013-09-26       Impact factor: 5.157

Review 4.  Transgenic animal models of neurodegeneration based on human genetic studies.

Authors:  Brandon K Harvey; Christopher T Richie; Barry J Hoffer; Mikko Airavaara
Journal:  J Neural Transm (Vienna)       Date:  2010-10-08       Impact factor: 3.575

5.  Binding of the three-repeat domain of tau to phospholipid membranes induces an aggregated-like state of the protein.

Authors:  Georg Künze; Patrick Barré; Holger A Scheidt; Lars Thomas; David Eliezer; Daniel Huster
Journal:  Biochim Biophys Acta       Date:  2012-04-06

6.  Isolation and characterization of antibody fragments selective for toxic oligomeric tau.

Authors:  Huilai Tian; Eliot Davidowitz; Patricia Lopez; Ping He; Philip Schulz; James Moe; Michael R Sierks
Journal:  Neurobiol Aging       Date:  2014-12-11       Impact factor: 4.673

7.  Ligand electronic properties modulate tau filament binding site density.

Authors:  Katryna Cisek; Jordan R Jensen; Nicolette S Honson; Kelsey N Schafer; Grace L Cooper; Jeff Kuret
Journal:  Biophys Chem       Date:  2012-09-11       Impact factor: 2.352

8.  Small-molecule mediated neuroprotection in an in situ model of tauopathy.

Authors:  Nicolette S Honson; Jordan R Jensen; Aida Abraha; Garth F Hall; Jeff Kuret
Journal:  Neurotox Res       Date:  2009-02-26       Impact factor: 3.911

9.  Structure-activity relationship of cyanine tau aggregation inhibitors.

Authors:  Edward Chang; Erin E Congdon; Nicolette S Honson; Karen E Duff; Jeff Kuret
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

Review 10.  Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  Expert Opin Ther Targets       Date:  2020-03-06       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.